Hana Insurance Secures Six-Month Exclusive Rights for "Neurocognitive Function Test Support" Rider

Hana Insurance announced on December 30 that it has acquired a six-month exclusive usage right for its newly developed "Neurocognitive Function Test Support Rider" for the "Hana The Next Dementia Nursing Care Insurance" product.

This new rider is characterized by providing coverage for the costs of neurocognitive function tests conducted before a dementia diagnosis. It was developed to help customers receive necessary tests early, rather than attributing memory decline simply to aging.

Neurocognitive function tests evaluate overall cognitive abilities such as memory, judgment, and concentration. These tests are used to detect dementia at a relatively early stage and to determine subsequent treatment and management plans. In medical practice, it has been consistently suggested that early management through such tests can help slow the progression of symptoms.

Reflecting this need, Hana Insurance has linked insurance coverage to essential tests that distinguish between normal aging and mild cognitive impairment. Under this rider, if a policyholder undergoes a covered neurocognitive function test for the purpose of diagnosing or treating mild cognitive impairment or dementia, based on a medical professional’s recommendation and after one year from policy enrollment, insurance benefits will be paid once for the first occurrence.

The covered tests include the Seoul Neuropsychological Screening Battery, CERAD-K (the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease assessment), and the LICA Elderly Cognitive Function Test, among other major diagnostic tools used in medical settings for dementia diagnosis and cognitive evaluation. Through this, policyholders can reduce the financial burden of tests that arise prior to a dementia diagnosis.

Hana The Next Dementia Nursing Care Insurance offers a comprehensive coverage system that spans the entire dementia process, from the testing stage to diagnosis benefits, outpatient and hospitalization expenses, and targeted dementia drug treatment costs. The industry’s first rider for in-home cognitive education visits for mild cognitive impairment, launched in partnership with Daekyo New Life, was granted a six-month exclusive usage right in August. More recently, a targeted dementia drug treatment cost rider was added, continuously strengthening the competitiveness of its dementia coverage.